Table 1 Demographic, pathologic, and therapy data, n = 213 patients. Parameters include all patients and are also sub-divided by HER2 status
Patient/lesion characteristics | All patients, n = 213 | ||
|---|---|---|---|
Total | HER2-positive | HER2-negatve | |
Age at FES, years (range) | 55 (23–79) | 52 (28–74) | 55 (23–79) |
Race | |||
Caucasian | 181 (85%) | ||
Asian | 9 (4%) | ||
Black or African American | 5 (2%) | ||
American Indian or Alaska Native | 4 (2%) | ||
Unknown or Other | 14 (7%) | ||
HER2 status (n, % of total) | 33 (15%) | 180 (85%) | |
Menopausal status | |||
Postmenopausal | 158 (74%) | 20 (61%) | 138 (77%) |
Premenopausal | 50 (23%) | 11 (33%) | 39 (22%) |
Male patients | 5 (2%) | 2 (6%) | 3 (2%) |
Histology | |||
Ductal | 158 (74%) | 28 (85%) | 130 (72%) |
Lobular | 35 (16%) | 4 (12%) | 31 (17%) |
Unknown | 11 (5%) | 1 (3%) | 10 (5%) |
Other | 5 (2%) | 0 (0%) | 5 (3%) |
Mixed | 4 (2%) | 0 (0%) | 4 (2%) |
Prior chemotherapy (n,%) | 140 (66%) | 26 (79%) | 114 (63%) |
Prior endocrine therapy (n,%) | 109 (51%) | 18 (55%) | 91 (51%) |
Therapy at time of FES (n,%) | |||
None | 119 (56%) | 16 (48%) | 103 (57%) |
Endocrine | 80 (38%) | 15 (45%) | 65 (36%) |
Chemotherapy | 12 (6%) | 2 (6%) | 10 (5%) |
Unknown | 2 (1%) | 0 (0%) | 2 (1%) |
Herceptin (HER2-positive only) | 11 (33%) | ||
Chemotherapy after FES (n,%) | 45 (21%) | 10 (30%) | 35 (19%) |
Endocrine therapy after FES | 142 (67%) | 19 (57%) | 123 (68%) |
Unknown therapy after FES | 13 (6%) | 2 (6%) | 11 (6%) |
FES scan machine | |||
Advance | 191 | 31 | 160 |
DSTE | 22 | 2 | 20 |
FDG scan machine | |||
Advance | 175 | 30 | 145 |
DSTE | 35 | 1 | 34 |
FDG and FES done on same machine | 185 | 29 | 156 |